Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Cited by (388)

Items 201–300 of 388

1. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial
   Davis, Kara L, Fox, Elizabeth, Merchant, Melinda S, Reid, Joel M, Kudgus, Rachel A, Liu, Xiaowei, Minard, Charles G, Voss, Stephan, Berg, Stacey L, Weigel, Brenda J et al. · 2020 · The Lancet Oncology
2. From mice to humans: developments in cancer immunoediting
   Teng, Michele W.L., Galon, Jerome, Fridman, Wolf-Herman, Smyth, Mark J. · 2015 · Journal of Clinical Investigation
3. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
   Stroud, Chipman RG, Hegde, Aparna, Cherry, Cynthia, Naqash, Abdul R, Sharma, Nitika, Addepalli, Srikala, Cherukuri, Sulochana, Parent, Teresa, Hardin, Jessica, Walker, Paul · 2019 · Journal of Oncology Pharmacy Practice
4. The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
   Williams, Patrick, Basu, Sreyashi, Garcia‐Manero, Guillermo, Hourigan, Christopher S., Oetjen, Karolyn A., Cortes, Jorge E., Ravandi, Farhad, Jabbour, Elias J., Al‐Hamal, Zainab, Konopleva, Marina et al. · 2019 · Cancer
5. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function
   Lee, Young-hee, Martin-Orozco, Natalia, Zheng, Peilin, Li, Jing, Zhang, Peng, Tan, Haidong, Park, Hyun Jung, Jeong, Mira, Chang, Seon Hee, Kim, Byung-Seok et al. · 2017 · Cell Research
6. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
   Faje, Alexander · 2016 · Pituitary
7. TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection
   Chew, Glen M., Fujita, Tsuyoshi, Webb, Gabriela M., Burwitz, Benjamin J., Wu, Helen L., Reed, Jason S., Hammond, Katherine B., Clayton, Kiera L., Ishii, Naoto, Abdel-Mohsen, Mohamed et al. · 2016 · PLoS Pathogens
8. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion
   Jiang, Yuanyuan, Zhan, Hanxiang · 2020 · Cancer Letters
9. Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer
   Overacre-Delgoffe, Abigail E., Bumgarner, Hannah J., Cillo, Anthony R., Burr, Ansen H.P., Tometich, Justin T., Bhattacharjee, Amrita, Bruno, Tullia C., Vignali, Dario A.A., Hand, Timothy W. · 2021 · Immunity
10. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression
    Bellucci, Roberto, Martin, Allison, Bommarito, Davide, Wang, Kathy, Hansen, Steen H, Freeman, Gordon J, Ritz, Jerome · 2015 · OncoImmunology
11. The immune system and cancer evasion strategies: therapeutic concepts
    Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., Hoeller, S. · 2016 · Journal of Internal Medicine
12. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
    Görgün, Güllü, Samur, Mehmet K., Cowens, Kristen B., Paula, Steven, Bianchi, Giada, Anderson, Julie E., White, Randie E., Singh, Ahaana, Ohguchi, Hiroto, Suzuki, Rikio et al. · 2015 · Clinical Cancer Research
13. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
    Saleh, Reem, Elkord, Eyad · 2020 · Seminars in Cancer Biology
14. Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
    Riera-Domingo, Carla, Audigé, Annette, Granja, Sara, Cheng, Wan-Chen, Ho, Ping-Chih, Baltazar, Fátima, Stockmann, Christian, Mazzone, Massimiliano · 2020 · Physiological Reviews
15. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment
    Tsukamoto, Hirotake, Fujieda, Koji, Miyashita, Azusa, Fukushima, Satoshi, Ikeda, Tokunori, Kubo, Yosuke, Senju, Satoru, Ihn, Hironobu, Nishimura, Yasuharu, Oshiumi, Hiroyuki · 2018 · Cancer Research
16. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs
    Gok Yavuz, Betul, Gunaydin, Gurcan, Gedik, M. Emre, Kosemehmetoglu, Kemal, Karakoc, Derya, Ozgur, Figen, Guc, Dicle · 2019 · Scientific Reports
17. Chemotherapy induces enrichment of CD47 ⁺ /CD73 ⁺ /PDL1 ⁺ immune evasive triple-negative breast cancer cells
    Samanta, Debangshu, Park, Youngrok, Ni, Xuhao, Li, Huili, Zahnow, Cynthia A., Gabrielson, Edward, Pan, Fan, Semenza, Gregg L. · 2018 · Proceedings of the National Academy of Sciences
18. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment
    Li, Xin, Xiang, Yanwei, Li, Fulun, Yin, Chengqian, Li, Bin, Ke, Xisong · 2019 · Frontiers in Immunology
19. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
    Choueiri, Toni K., Fishman, Mayer N., Escudier, Bernard, McDermott, David F., Drake, Charles G., Kluger, Harriet, Stadler, Walter M., Perez-Gracia, Jose Luis, McNeel, Douglas G., Curti, Brendan et al. · 2016 · Clinical Cancer Research
20. Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor
    Garcia Fortanet, Jorge, Chen, Christine Hiu-Tung, Chen, Ying-Nan P., Chen, Zhouliang, Deng, Zhan, Firestone, Brant, Fekkes, Peter, Fodor, Michelle, Fortin, Pascal D., Fridrich, Cary et al. · 2016 · Journal of Medicinal Chemistry
21. The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment
    Haist, Maximilian, Stege, Henner, Grabbe, Stephan, Bros, Matthias · 2021 · Cancers
22. β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy
    Bucsek, Mark J., Qiao, Guanxi, MacDonald, Cameron R., Giridharan, Thejaswini, Evans, Lauren, Niedzwecki, Brian, Liu, Haichao, Kokolus, Kathleen M., Eng, Jason W.-L., Messmer, Michelle N. et al. · 2017 · Cancer Research
23. The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance
    Fearon, Douglas T. · 2014 · Cancer Immunology Research
24. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
    Karachaliou, Niki, Gonzalez-Cao, Maria, Crespo, Guillermo, Drozdowskyj, Ana, Aldeguer, Erika, Gimenez-Capitan, Ana, Teixido, Cristina, Molina-Vila, Miguel Angel, Viteri, Santiago, De Los Llanos Gil, Maria et al. · 2018 · Therapeutic Advances in Medical Oncology
25. TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
    Park, Benjamin V., Freeman, Zachary T., Ghasemzadeh, Ali, Chattergoon, Michael A., Rutebemberwa, Alleluiah, Steigner, Jordana, Winter, Matthew E., Huynh, Thanh V., Sebald, Suzanne M., Lee, Se-Jin et al. · 2016 · Cancer Discovery
26. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
    Pauken, Kristen E., Dougan, Michael, Rose, Noel R., Lichtman, Andrew H., Sharpe, Arlene H. · 2019 · Trends in Immunology
27. LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
    Maruhashi, Takumi, Okazaki, Il-mi, Sugiura, Daisuke, Takahashi, Suzuka, Maeda, Takeo K., Shimizu, Kenji, Okazaki, Taku · 2018 · Nature Immunology
28. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
    Delivanis, Danae A, Gustafson, Michael P, Bornschlegl, Svetlana, Merten, Michele M, Kottschade, Lisa, Withers, Sarah, Dietz, Allan B, Ryder, Mabel · 2017 · The Journal of Clinical Endocrinology & Metabolism
29. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements
    Zhang, Shang-Min, Cai, Wesley L., Liu, Xiaoni, Thakral, Durga, Luo, Jiesi, Chan, Lok Hei, McGeary, Meaghan K., Song, Eric, Blenman, Kim R. M., Micevic, Goran et al. · 2021 · Nature
30. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
    Lee, Nayoung, Zakka, Labib R., Mihm, Martin C., Schatton, Tobias · 2016 · Pathology
31. Development of PARP and immune-checkpoint inhibitor combinations
    Stewart, Ross A, Pilié, Patrick G, Yap, Timothy A · 2018 · Cancer Research
32. Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells
    Cañellas-Socias, Adrià, Cortina, Carme, Hernando-Momblona, Xavier, Palomo-Ponce, Sergio, Mulholland, Eoghan J., Turon, Gemma, Mateo, Lidia, Conti, Sefora, Roman, Olga, Sevillano, Marta et al. · 2022 · Nature
33. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer: A Review
    Sacher, Adrian G., Gandhi, Leena · 2016 · JAMA Oncology
34. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200
    Noman, Muhammad Zaeem, Janji, Bassam, Abdou, Abderemane, Hasmim, Meriem, Terry, Stéphane, Tan, Tuan Zea, Mami-Chouaib, Fathia, Thiery, Jean Paul, Chouaib, Salem · 2017 · OncoImmunology
35. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
    Lind, Hanne, Gameiro, Sofia R, Jochems, Caroline, Donahue, Renee N., Strauss, Julius, Gulley, James L, Palena, Claudia, Schlom, Jeffrey · 2020 · Journal for ImmunoTherapy of Cancer
36. Chemoimmunotherapy: Reengineering Tumor Immunity
    Chen, Gang, Emens, Leisha A. · 2013 · Cancer Immunology, Immunotherapy
37. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
    Zheng, Xichen, Fang, Zhaoxu, Liu, Xiaomei, Deng, Shengming, Zhou, Pei, Wang, Xuexiang, Zhang, Chenglin, Yin, Rongping, Hu, Haitian, Chen, Xiaolan et al. · 2018 · Journal of Clinical Investigation
38. Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation
    Yu, Man, Peng, Zhengxin, Qin, Min, Liu, Yang, Wang, Jingning, Zhang, Cai, Lin, Jiaming, Dong, Tianqi, Wang, Lulu, Li, Shasha et al. · 2021 · Molecular Cell
39. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
    Ngiow, Shin Foong, Young, Arabella, Jacquelot, Nicolas, Yamazaki, Takahiro, Enot, David, Zitvogel, Laurence, Smyth, Mark J. · 2015 · Cancer Research
40. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
    Oh, David Y., Cham, Jason, Zhang, Li, Fong, Grant, Kwek, Serena S., Klinger, Mark, Faham, Malek, Fong, Lawrence · 2017 · Cancer Research
41. In vivo discovery of immunotherapy targets in the tumour microenvironment
    Zhou, Penghui, Shaffer, Donald R., Alvarez Arias, Diana A., Nakazaki, Yukoh, Pos, Wouter, Torres, Alexis J., Cremasco, Viviana, Dougan, Stephanie K., Cowley, Glenn S., Elpek, Kutlu et al. · 2014 · Nature
42. Comprehensive T cell repertoire characterization of non-small cell lung cancer
    Reuben, Alexandre, Zhang, Jiexin, Chiou, Shin-Heng, Gittelman, Rachel M., Li, Jun, Lee, Won-Chul, Fujimoto, Junya, Behrens, Carmen, Liu, Xiaoke, Wang, Feng et al. · 2020 · Nature Communications
43. Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
    Moslehi, Javid, Lichtman, Andrew H., Sharpe, Arlene H., Galluzzi, Lorenzo, Kitsis, Richard N. · 2021 · Journal of Clinical Investigation
44. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
    Majidpoor, Jamal, Mortezaee, Keywan · 2021 · Clinical Immunology
45. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy
    Lines, J. Louise, Sempere, Lorenzo F., Broughton, Thomas, Wang, Li, Noelle, Randolph · 2014 · Cancer Immunology Research
46. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
    LaMarche, Matthew J., Acker, Michael, Argintaru, Andreea, Bauer, Daniel, Boisclair, Julie, Chan, Homan, Chen, Christine Hiu-Tung, Chen, Ying-Nan, Chen, Zhouliang, Deng, Zhan et al. · 2020 · Journal of Medicinal Chemistry
47. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
    Hossain, Dewan Md Sakib, Javaid, Sarah, Cai, Mingmei, Zhang, Chunsheng, Sawant, Anandi, Hinton, Marlene, Sathe, Manjiri, Grein, Jeff, Blumenschein, Wendy, Pinheiro, Elaine M. et al. · 2018 · Journal of Clinical Investigation
48. Metabolomic adaptations and correlates of survival to immune checkpoint blockade
    Li, Haoxin, Bullock, Kevin, Gurjao, Carino, Braun, David, Shukla, Sachet A., Bossé, Dominick, Lalani, Aly-Khan A., Gopal, Shuba, Jin, Chelsea, Horak, Christine et al. · 2019 · Nature Communications
49. Molecular pathways and therapeutic targets in lung cancer
    Shtivelman, Emma, Hensing, Thomas, Simon, George R., Dennis, Phillip A., Otterson, Gregory A., Bueno, Raphael, Salgia, Ravi · 2014 · Oncotarget
50. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
    Boyiadzis, Michael M., Kirkwood, John M., Marshall, John L., Pritchard, Colin C., Azad, Nilofer S., Gulley, James L. · 2018 · Journal for ImmunoTherapy of Cancer
51. TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts
    Grauel, Angelo L., Nguyen, Beverly, Ruddy, David, Laszewski, Tyler, Schwartz, Stephanie, Chang, Jonathan, Chen, Julie, Piquet, Michelle, Pelletier, Marc, Yan, Zheng et al. · 2020 · Nature Communications
52. The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
    Huff, Wei X., Kwon, Jae Hyun, Henriquez, Mario, Fetcko, Kaleigh, Dey, Mahua · 2019 · International Journal of Molecular Sciences
53. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment
    Yang, Li, Li, Aitian, Lei, Qingyang, Zhang, Yi · 2019 · Journal of Hematology & Oncology
54. Hostile, Hypoxia–A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists
    Sitkovsky, Michail V., Hatfield, Stephen, Abbott, Robert, Belikoff, Bryan, Lukashev, Dmitriy, Ohta, Akio · 2014 · Cancer Immunology Research
55. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study
    Abu-Sbeih, Hamzah, Ali, Faisal S., Alsaadi, Dana, Jennings, Joseph, Luo, Wenyi, Gong, Zimu, Richards, David M., Charabaty, Aline, Wang, Yinghong · 2018 · Journal for ImmunoTherapy of Cancer
56. Engineering patient-specific cancer immunotherapies
    Scheetz, Lindsay, Park, Kyung Soo, Li, Qiao, Lowenstein, Pedro R., Castro, Maria G., Schwendeman, Anna, Moon, James J. · 2019 · Nature Biomedical Engineering
57. Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
    Lussier, Danielle M, Johnson, John L, Hingorani, Pooja, Blattman, Joseph N · 2015 · Journal for ImmunoTherapy of Cancer
58. Liver transplantation immunology: immunosuppression, rejection, and immunomodulation
    Montano-Loza, Aldo J., Rodríguez-Perálvarez, Manuel L., Pageaux, George-Philippe, Sanchez-Fueyo, Alberto, Feng, Sandy · 2023 · Journal of Hepatology
59. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
    Indini, Alice, Di Guardo, Lorenza, Cimminiello, Carolina, Prisciandaro, Michele, Randon, Giovanni, De Braud, Filippo, Del Vecchio, Michele · 2019 · Journal of Cancer Research and Clinical Oncology
60. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
    Koelzer, Viktor H., Rothschild, Sacha I., Zihler, Deborah, Wicki, Andreas, Willi, Berenika, Willi, Niels, Voegeli, Michèle, Cathomas, Gieri, Zippelius, Alfred, Mertz, Kirsten D. · 2016 · Journal for ImmunoTherapy of Cancer
61. Acquired and intrinsic resistance in cancer immunotherapy
    Kelderman, Sander, Schumacher, Ton N.M., Haanen, John B.A.G. · 2014 · Molecular Oncology
62. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation
    Vendetti, Frank P., Karukonda, Pooja, Clump, David A., Teo, Troy, Lalonde, Ronald, Nugent, Katriana, Ballew, Matthew, Kiesel, Brian F., Beumer, Jan H., Sarkar, Saumendra N. et al. · 2018 · Journal of Clinical Investigation
63. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
    Lee, Lik Hang, Cavalcanti, Marcela S, Segal, Neil H, Hechtman, Jaclyn F, Weiser, Martin R, Smith, J Joshua, Garcia-Aguilar, Julio, Sadot, Eran, Ntiamoah, Peter, Markowitz, Arnold J et al. · 2016 · Modern Pathology
64. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Badros, Ashraf, Hyjek, Elizabeth, Ma, Ning, Lesokhin, Alexander, Dogan, Ahmet, Rapoport, Aaron P., Kocoglu, Mehmet, Lederer, Emily, Philip, Sunita, Milliron, Todd et al. · 2017 · Blood
65. <i>TP53</i> mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
    Sallman, David A., McLemore, Amy F., Aldrich, Amy L., Komrokji, Rami S., McGraw, Kathy L., Dhawan, Abhishek, Geyer, Susan, Hou, Hsin-An, Eksioglu, Erika A., Sullivan, Amy et al. · 2020 · Blood
66. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
    Reuben, Alexandre, Spencer, Christine N., Prieto, Peter A., Gopalakrishnan, Vancheswaran, Reddy, Sangeetha M., Miller, John P., Mao, Xizeng, De Macedo, Mariana Petaccia, Chen, Jiong, Song, Xingzhi et al. · 2017 · npj Genomic Medicine
67. The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment
    Hendry, Shona A., Farnsworth, Rae H., Solomon, Benjamin, Achen, Marc G., Stacker, Steven A., Fox, Stephen B. · 2016 · Frontiers in Immunology
68. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer
    Phillips, Therese, Simmons, Pauline, Inzunza, Hector D., Cogswell, John, Novotny, James, Taylor, Clive, Zhang, Xiaoling · 2015 · Applied Immunohistochemistry &amp; Molecular Morphology
69. Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies
    Chen, Jonathan H., Pezhouh, Maryam K., Lauwers, Gregory Y., Masia, Ricard · 2017 · American Journal of Surgical Pathology
70. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues
    Majzner, Robbie G., Simon, Jason S., Grosso, Joseph F., Martinez, Daniel, Pawel, Bruce R., Santi, Mariarita, Merchant, Melinda S., Geoerger, Birgit, Hezam, Imene, Marty, Virginie et al. · 2017 · Cancer
71. PD-1 expression on dendritic cells suppresses CD8⁺T cell function and antitumor immunity
    Lim, Tong Seng, Chew, Valerie, Sieow, Je Lin, Goh, Siting, Yeong, Joe Poh-Sheng, Soon, Ai Ling, Ricciardi-Castagnoli, Paola · 2016 · OncoImmunology
72. The promising immune checkpoint LAG‐3 in cancer immunotherapy: from basic research to clinical application
    Huo, Jin-Ling, Wang, Ya-Tao, Fu, Wen-Jia, Lu, Nan, Liu, Zhang-Suo · 2022 · Frontiers in Immunology
73. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
    Ruf, Melanie, Moch, Holger, Schraml, Peter · 2016 · International Journal of Cancer
74. A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
    David, Justin M., Dominguez, Charli, McCampbell, Kristen K., Gulley, James L., Schlom, Jeffrey, Palena, Claudia · 2017 · OncoImmunology
75. Technological advances in cancer immunity: from immunogenomics to single‐cell analysis and artificial intelligence
    Xu, Ying, Su, Guan-Hua, Ma, Ding, Xiao, Yi, Shao, Zhi-Ming, Jiang, Yi-Zhou · 2021 · Signal Transduction and Targeted Therapy
76. Interaction of SHP‐2 SH2 domains with PD‐1 ITSM induces PD‐1 dimerization and SHP‐2 activation
    Patsoukis, Nikolaos, Duke-Cohan, Jonathan S., Chaudhri, Apoorvi, Aksoylar, Halil-Ibrahim, Wang, Qi, Council, Asia, Berg, Anders, Freeman, Gordon J., Boussiotis, Vassiliki A. · 2020 · Communications Biology
77. Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma
    Deng, Haijing, Kan, Anna, Lyu, Ning, Mu, Luwen, Han, Yi, Liu, Longzhong, Zhang, Yanyu, Duan, Youfa, Liao, Shuangye, Li, Shaolong et al. · 2020 · Liver Cancer
78. Genetic evolution of T-cell resistance in the course of melanoma progression
    Sucker, Antje, Zhao, Fang, Real, Birgit, Heeke, Christina, Bielefeld, Nicola, Maβen, Stefan, Horn, Susanne, Moll, Iris, Maltaner, Raffaela, Horn, Peter A. et al. · 2014 · Clinical Cancer Research
79. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
    Wu, Xinqi, Giobbie-Hurder, Anita, Liao, Xiaoyun, Connelly, Courtney, Connolly, Erin M., Li, Jingjing, Manos, Michael P., Lawrence, Donald, McDermott, David, Severgnini, Mariano et al. · 2017 · Cancer Immunology Research
80. Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel–Lindau gene mutation status
    Messai, Yosra, Gad, Sophie, Noman, Muhammad Zaeem, Le Teuff, Gwenael, Couve, Sophie, Janji, Bassam, Kammerer, Solenne Florence, Rioux-Leclerc, Nathalie, Hasmim, Meriem, Ferlicot, Sophie et al. · 2016 · European Urology
81. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer
    Zhao, Sha, Gao, Guanghui, Li, Wei, Li, Xuefei, Zhao, Chao, Jiang, Tao, Jia, Yijun, He, Yayi, Li, Aiwu, Su, Chunxia et al. · 2019 · Lung Cancer
82. Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
    Lee, Hyunju, Hodi, F. Stephen, Giobbie-Hurder, Anita, Ott, Patrick A., Buchbinder, Elizabeth I., Haq, Rizwan, Tolaney, Sara, Barroso-Sousa, Romualdo, Zhang, Kevin, Donahue, Hilary et al. · 2017 · Cancer Immunology Research
83. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
    Lin, Kailong, Cheng, Jianan, Yang, Tao, Li, Yongsheng, Zhu, Bo · 2015 · Biochemical and Biophysical Research Communications
84. Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity
    Liu, Chang, Somasundaram, Ashwin, Manne, Sasikanth, Gocher, Angela M., Szymczak-Workman, Andrea L., Vignali, Kate M., Scott, Ellen N., Normolle, Daniel P., John Wherry, E., Lipson, Evan J. et al. · 2020 · Nature Immunology
85. PD-1/PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors
    Seifert, Adrian M., Zeng, Shan, Zhang, Jennifer Q., Kim, Teresa S., Cohen, Noah A., Beckman, Michael J., Medina, Benjamin D., Maltbaek, Joanna H., Loo, Jennifer K., Crawley, Megan H. et al. · 2017 · Clinical Cancer Research
86. High microsatellite instability (MSI-H) colorectal carcinoma: A brief review of predictive biomarkers in the era of personalized medicine
    Gatalica, Zoran, Vranic, Semir, Xiu, Joanne, Swensen, Jeffrey, Reddy, Sandeep · 2016 · Familial Cancer
87. HIF1α and HIF2α independently activate SRC to promote melanoma metastases
    Hanna, Sara C., Krishnan, Bhavani, Bailey, Sean T., Moschos, Stergios J., Kuan, Pei-Fen, Shimamura, Takeshi, Osborne, Lukas D., Siegel, Marni B., Duncan, Lyn M., O’Brien, E. Tim et al. · 2013 · Journal of Clinical Investigation
88. Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy
    Chuckran, Christopher A, Liu, Chang, Bruno, Tullia C, Workman, Creg J, Vignali, Dario AA · 2020 · Journal for ImmunoTherapy of Cancer
89. Non-conventional Inhibitory CD4+Foxp3−PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity
    Zappasodi, Roberta, Budhu, Sadna, Hellmann, Matthew D., Postow, Michael A., Senbabaoglu, Yasin, Manne, Sasikanth, Gasmi, Billel, Liu, Cailian, Zhong, Hong, Li, Yanyun et al. · 2018 · Cancer Cell
90. An engineered tumor-on-a-chip device with breast cancer–immune cell interactions for assessing T-cell recruitment
    Aung, Aereas, Kumar, Vardhman, Theprungsirikul, Jomkuan, Davey, Shruti K., Varghese, Shyni · 2020 · Cancer Research
91. Tumor-specific IL-9–producing CD8 ⁺ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers
    Lu, Yong, Hong, Bangxing, Li, Haiyan, Zheng, Yuhuan, Zhang, Mingjun, Wang, Siqing, Qian, Jianfei, Yi, Qing · 2014 · Proceedings of the National Academy of Sciences
92. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
    on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group, Verzoni, Elena, Cartenì, Giacomo, Cortesi, Enrico, Giannarelli, Diana, De Giglio, Andrea, Sabbatini, Roberto, Buti, Sebastiano, Rossetti, Sabrina, Cognetti, Francesco et al. · 2019 · Journal for ImmunoTherapy of Cancer
93. Treatment of NRAS-mutant melanoma
    Johnson, Douglas B., Puzanov, Igor · 2015 · Current Treatment Options in Oncology
94. PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and anti-PD1 responses
    Sai, Jiqing, Owens, Philip, Novitskiy, Sergey V., Hawkins, Oriana E., Vilgelm, Anna E., Yang, Jinming, Sobolik, Tammy, Lavender, Nicole, Johnson, Andrew C., McClain, Colt et al. · 2017 · Clinical Cancer Research
95. DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune cell activation
    Xiao, Qian, Wu, Jibo, Wang, Wei-Jia, Chen, Shiyang, Zheng, Yingxia, Yu, Xiaoqing, Meeth, Katrina, Sahraei, Mahnaz, Bothwell, Alfred L M, Chen, Lieping et al. · 2018 · Nature Medicine
96. Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies
    Orlov, Steven, Salari, Farnaz, Kashat, Lawrence, Walfish, Paul G. · 2015 · The Journal of Clinical Endocrinology &amp; Metabolism
97. A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression
    Kjaergaard, Jorgen, Hatfield, Stephen, Jones, Graham, Ohta, Akio, Sitkovsky, Michail · 2018 · The Journal of Immunology
98. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials
    Costa, Ricardo, Carneiro, Benedito A., Agulnik, Mark, Rademaker, Alfred W., Pai, Sachin G., Villaflor, Victoria M., Cristofanilli, Massimo, Sosman, Jeffrey A., Giles, Francis J. · 2017 · Oncotarget
99. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept
    Colen, Rivka R., Fujii, Takeo, Bilen, Mehmet Asim, Kotrotsou, Aikaterini, Abrol, Srishti, Hess, Kenneth R., Hajjar, Joud, Suarez-Almazor, Maria E., Alshawa, Anas, Hong, David S. et al. · 2018 · Investigational New Drugs
100. Clinical pharmacology considerations for the development of immune checkpoint inhibitors
     Sheng, Jennifer, Srivastava, Shivani, Sanghavi, Kinjal, Lu, Zheng, Schmidt, Brian J., Bello, Akintunde, Gupta, Manish · 2017 · The Journal of Clinical Pharmacology